Emprocell Clinical Research Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 17-12-2024
- Paid Up Capital ₹ 4.61 Cr
as on 17-12-2024
- Company Age 18 Year, 8 Months
- Last Filing with ROC 31 Mar 2020
- Revenue -51.50%
(FY 2020)
- Profit 14.89%
(FY 2020)
- Ebitda -3.68%
(FY 2020)
- Net Worth -13.59%
(FY 2020)
- Total Assets -8.68%
(FY 2020)
About Emprocell Clinical Research
The Corporate was formerly known as Em Pro Cell Research Private Limited. The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.61 Cr, as per Ministry of Corporate Affairs (MCA) records.
Vladimir Babiy, Svetlana Babiy, Vasily Babiy, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24231MH2006PTC161334
- Company No.
161334
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Apr 2006
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationNavi Mumbai, Maharashtra
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Emprocell Clinical Research?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vladimir Babiy  | Director | 09-May-2006 | Current |
| Svetlana Babiy | Director | 09-May-2006 | Current |
| Vasily Babiy | Director | 19-Aug-2012 | Current |
Viktor Radchenko  | Director | 10-Jun-2006 | Current |
| Oleksandr Kukharchuk | Alternate Director | 19-Aug-2012 | Current |
| Elena Babiy | Director | 09-May-2006 | Current |
Financial Performance of Emprocell Clinical Research.
Emprocell Clinical Research Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 51.5% decrease. The company also saw a substantial improvement in profitability, with a 14.89% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.59%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Emprocell Clinical Research?
In 2020, Emprocell Clinical Research had a promoter holding of 95.52% and a public holding of 4.48%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Emprocell Clinical Research?
Emprocell Clinical Research has a workforce of 5 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Emprocell Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emprocell Clinical Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
